Full Injunction Granted

United Therapeutics converts its patent-trial win into a strong post-trial remedy, persuading the court that Yutrepia sales would irreparably harm Tyvaso-related revenue. This is the most likely path because the company has already won the patent case and is now asking for the most restrictive relief available.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.